Biogen has decided to end its collaboration with Sage Therapeutics on the SAGE-324 molecule due to disappointing clinical results. However, the partnership continues for ZURZUVAE® development. Sage gains perpetual rights to certain Biogen technologies related to SAGE-324 following the termination.